Study to confirm the safety profile of telmisartan (benefit-risk ratio) under normal conditions of use after market launch and to supplement the present data on the safety of telmisartan. Furthermore to assess effectiveness of a single dose of telmisartan per day to control blood pressure for 24 hours, especially during the last few hours of the dosage interval. Additionally to evaluate compliance with treatment, as an indirect measurement, and to confirm the efficacy and possible risks associated with treatment.
Study Type
OBSERVATIONAL
Enrollment
10,333
Assessment of changes in heart rate
Time frame: Baseline, up to 8 weeks after start of treatment
Assessment for patients with changes in laboratory values
Time frame: Baseline, up to 8 weeks after start of treatment
Number of patients with adverse events
Time frame: Up to 8 weeks after start of treatment
Changes in mean systolic and diastolic blood pressure values
Measured by means of ambulatory blood pressure monitoring (ABPM) over 24 hours
Time frame: Baseline, up to 8 weeks after start of treatment
Changes in mean systolic and diastolic blood pressure values
Measured three times at intervals of two minutes with the patient seated and lying down for 5 minutes, using a sphygmomanometer
Time frame: Baseline, up to 8 weeks after start of treatment
Evaluation of treatment compliance as percentage of tablets planned
(number of tablets taken / total number of days) x 100
Time frame: Up to 8 weeks after start of treatment
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.